{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T03:14:04Z","timestamp":1767237244616,"version":"3.40.3"},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,4,1]]},"DOI":"10.2169\/internalmedicine.3961-24","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T22:10:18Z","timestamp":1725401418000},"page":"1089-1092","source":"Crossref","is-referenced-by-count":2,"title":["First Reported Case of Pure Red Cell Aplasia Related to Sotorasib"],"prefix":"10.2169","volume":"64","author":[{"given":"Katsuhiro","family":"Itogawa","sequence":"first","affiliation":[{"name":"Division of Pulmonary Medicine, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Nakata","sequence":"additional","affiliation":[{"name":"Division of Hematology, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikari","family":"Amari","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Tahara","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomu","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Division of Hematology, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Nomura","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Shiihara","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Nagai","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Ohta","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Jichi Medical University Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with <i>KRAS<\/i><sup><i>G12C<\/i><\/sup> mutation: a randomised, open-label, phase 3 trial. Lancet 401: 733-746, 2023.","DOI":"10.1016\/S0140-6736(23)00221-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kawakado K, Ito S, Kono K, Mitarai Y, Yanagawa T, Nagasaki M. Pure red cell aplasia induced by atezolizumab in a patient with small-cell lung cancer successfully treated with steroid therapy: a case report. Case Rep Oncol 16: 1592-1597, 2023.","DOI":"10.1159\/000535468"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Watanabe K, Kitadai R, Kitagawa S, Toya T, Hosomi Y. Durvalumab-induced secondary pure red cell aplasia successfully treated with cyclosporin. JTO Clin Res Rep 1: 100046, 2020.","DOI":"10.1016\/j.jtocrr.2020.100046"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 142: 505-514, 2008.","DOI":"10.1111\/j.1365-2141.2008.07216.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 58: 1351-1353, 2009.","DOI":"10.1007\/s00262-008-0627-x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. G\u00e9rard A, Romani S, Van-Obberghen E, et al. Case report: successful treatment of steroid-refractory immune checkpoint inhibitor-related pure red cell aplasia with cyclosporin. Front Oncol 10: 1760, 2020.","DOI":"10.3389\/fonc.2020.01760"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Guo Q, Gao J, Guo H, Xie J, Cheng J. Immune checkpoint inhibitor-induced pure red cell aplasia: case series and large-scale pharmacovigilance analysis. Int Immunopharmacol 114: 109490, 2023.","DOI":"10.1016\/j.intimp.2022.109490"},{"key":"8","doi-asserted-by":"crossref","first-page":"000058","DOI":"10.1136\/esmoopen-2016-000058","volume":"1","author":"BS Poudyal","year":"2016","unstructured":"8. Poudyal BS, Tuladhar S, Gyawali B. TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib. ESMO Open 1: 000058, 2016.","journal-title":"ESMO Open","ISSN":"https:\/\/id.crossref.org\/issn\/2059-7029","issn-type":"print"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ogata H, Yamamoto Y, Harada T, et al. Severe aplastic anemia during osimertinib therapy in a patient with egfr tyrosine kinase inhibitor-resistant non-small cell lung cancer. J Thorac Oncol 12: 46-47, 2017.","DOI":"10.1016\/j.jtho.2016.12.023"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. ReeKim S, Han J, Yoon JH, Kim JO, Kang JH. Severe aplastic anemia during osimertinib treatment in a non-small cell lung cancer patient harboring EGFR T790M mutation. Hematol Med Oncol 3: 2018.","DOI":"10.15761\/HMO.1000165"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Sala L, Mancin M, Pastore A, et al. Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: a case report and literature review. Lung Cancer 142: 120-122, 2020.","DOI":"10.1016\/j.lungcan.2020.02.019"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. DiMarino P, Chiapperino C, Primavera FC, et al. Pancytopenia during osimertinib treatment in a patient with EGFR-mutated non-small cell lung cancer. Onco Targets Ther 15: 407-410, 2022.","DOI":"10.2147\/OTT.S315385"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Abdalhadi A, Omar NE, Kohla S, Aakel H, Ekeibed Y, Mohsen R. Aplastic anemia secondary to adjuvant osimertinib therapy: a case report and a review of literature. Front Oncol 14: 1275275, 2024.","DOI":"10.3389\/fonc.2024.1275275"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mu\u00f1oz-Maldonado C, Zimmer Y, Medov\u00e1 M. A comparative analysis of individual RAS mutations in cancer biology. Front Oncol 9: 1088, 2019.","DOI":"10.3389\/fonc.2019.01088"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hochstetler CL, Feng Y, Sacma M, et al. KRas<sup>G12D<\/sup> expression in the bone marrow vascular niche affects hematopoiesis with inflammatory signals. Exp Hematol 79: 3-15. e4, 2019.","DOI":"10.1016\/j.exphem.2019.10.003"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Canon J, Rex K, Saiki AY, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575: 217-223, 2019.","DOI":"10.1038\/s41586-019-1694-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Desai A, Rakshit S, Bansal R, et al. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: a brief report. Cancer Treat Res Commun 36: 100743, 2023.","DOI":"10.1016\/j.ctarc.2023.100743"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/7\/64_3961-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T03:52:27Z","timestamp":1743825147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/7\/64_3961-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3961-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"3961-24"}}